Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT06859008 · RECRUITING

Trial details

NCT number: NCT06859008
Sponsor: City of Hope Medical Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Nodal Marginal Zone Lymphoma Recurrent Splenic Marginal Zone Lymphoma Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Refractory Diffuse Large B-Cell Lymphoma

Start date: 2025-08-25
Primary completion: 2029-01-31
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.